MEKK2 mediates an alternative β-catenin pathway that promotes bone formation
- 16 February 2016
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (9) , E1226-E1235
Abstract
Proper tuning of β-catenin activity in osteoblasts is required for bone homeostasis, because both increased and decreased β-catenin activity have pathologic consequences. In the classical pathway for β-catenin activation, stimulation with WNT ligands suppresses constitutive phosphorylation of β-catenin by glycogen synthase kinase 3β, preventing β-catenin ubiquitination and proteasomal degradation. Here, we have found that mitogen-activated protein kinase kinase kinase 2 (MAP3K2 or MEKK2) mediates an alternative pathway for β-catenin activation in osteoblasts that is distinct from the canonical WNT pathway. FGF2 activates MEKK2 to phosphorylate β-catenin at serine 675, promoting recruitment of the deubiquitinating enzyme, ubiquitin-specific peptidase 15 (USP15). USP15 in turn prevents the basal turnover of β-catenin by inhibiting its ubiquitin-dependent proteasomal degradation, thereby enhancing WNT signaling. Analysis of MEKK2-deficient mice and genetic interaction studies between Mekk2- and β-catenin–null alleles confirm that this pathway is an important physiologic regulator of bone mass in vivo. Thus, an FGF2/MEKK2 pathway mediates an alternative nonclassical pathway for β-catenin activation, and this pathway is a key regulator of bone formation by osteoblasts. Significance Here, we report a previously unidentified alternative pathway mediated by mitogen-activated protein kinase kinase kinase 2 (MEKK2) for the activation of β-catenin in osteoblasts that is distinct from the classical glycogen synthase kinase 3β (GSK3β)-mediated degradation pathway. The GSK3β pathway regulates β-catenin stability via β-catenin ubiquitination, and its inhibition prevents β-catenin degradation. The MEKK2 pathway instead rescues ubiquitinated β-catenin from degradation via deubiquitination. This pathway plays a critical role in controlling bone mass in vivo, and targeting this pathway may offer an attractive approach for the therapeutic regulation of β-catenin activity.Keywords
Funding Information
- Burroughs Wellcome Fund (1014758)
- HHS | NIH | NIH Office of the Director (1DP5OD021351)
This publication has 40 references indexed in Scilit:
- Wnt/beta-Catenin Signaling and Small Molecule InhibitorsCurrent Pharmaceutical Design, 2013
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- β-catenin promotes bone formation and suppresses bone resorption in postnatal growing miceJournal of Bone and Mineral Research, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome–like skeletal defects induced by Pdk1 or Cbp mutations in miceJournal of Clinical Investigation, 2012
- MLK3 regulates bone development downstream of the faciogenital dysplasia protein FGD1 in miceJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 2 Stimulation of Osteoblast Differentiation and Bone Formation Is Mediated by Modulation of the Wnt Signaling PathwayJournal of Biological Chemistry, 2011
- The Kinases MEKK2 and MEKK3 Regulate Transforming Growth Factor-β-Mediated Helper T Cell DifferentiationImmunity, 2011
- CHIP‐dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic responseThe EMBO Journal, 2010
- Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast DifferentiationDevelopmental Cell, 2005